Showing results (211-220 of 395) with videos related to
Sort By:
Pageof 40
Hemasphere|July 15, 2021
The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma CellsMoritz Bewarder, Maximilian Kiefer, Helene Will, et al.Cancers|October 23, 2021
Landscape of 4D Cell Interaction in Hodgkin and Non-Hodgkin LymphomasSylvia Hartmann, Sonja Scharf, Yvonne Steiner, et al.Leukemia & Lymphoma|September 21, 2018
New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenanceNatali Pflug, Paula Cramer, Sandra Robrecht, et al.Leukemia & Lymphoma|May 2, 2013
Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study GroupPaula Cramer, Anna-Maria Fink, Raymonde Busch, et al.Leukemia & Lymphoma|July 9, 2016
Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapyRoxanne C Jewell, Thomas J Kipps, Jan Dürig, et al.Oncoimmunology|July 30, 2016
Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiotaNatali Pflug, Sandra Kluth, Jörg J Vehreschild, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2008
Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysisJohannes Schetelig, Anja van Biezen, Ronald Brand, et al.Leukemia|May 16, 2024
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 updateJitka Malcikova, Sarka Pavlova, Panagiotis Baliakas, et al.European Journal of Nuclear Medicine and Molecular Imaging|April 30, 2021
FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trialsDominic Kaddu-Mulindwa, Bettina Altmann, Gerhard Held, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2009
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study GroupStephan Stilgenbauer, Thorsten Zenz, Dirk Winkler, et al.Pageof 40